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Abstract P164 - Table 1 
Characteristic Responder Non-Responder P-value 
Sample Size 
Age (years) mean (s.d.) 
Female n (%) 
Race n (%) White 
Black 
Other 
Body Mass Index (kg/m 2) mean (s.d.) 
Duration of OA Symptoms (years) mean (s.d.) 
Acetaminophen Use (500mg tablets/day) mean (s.d.) 
ARA Functional Class n (%) Class I 
Class II 
Class III 
Kellgren & Lawrence n (%) Grade 2 
Grade 3 
Patient Global Assessment of Disease Status mean (s.d) 
Physician Global Assessment of Disease Status mean (s.d.) 
WOMAC Pain Score (mm) mean (s.d.) 
WOMAC Stiffness Score (mm) mean (s.d.) 
WOMAC Function Score (mm) mean (s.d.) 
HAQ Alternative Disability Score mean (s.d.) 
HAQ Pain Score mean (s.d.) 
SF-36 Physical Component Score mean (s.d.) 
SF-36 Mental Component Score mean (s.d.) 
162 151 
58.5 (9.5) 57.9 (10.3) 0.61 
121 (64.4) 79 (63.2) 0.83 
151 (80.3) 96 (76.8) 0.69 
21 (11.2) 18 (14.4) 
16 (8.5) 11 (8.8) 
31.8 (6.6) 32.0 (8.3) 0.75 
8.7 (8.7) 10.6 (9.5) 0.07 
1.1 (2.0) 1.4 (2.1) 0.12 
44 (23.4) 36 (28.8) 0.42 
107 (56.9) 62 (49.6) 
37 (19.7) 27 (21.6) 
113 (60.1) 66 (52.8) 0.20 
75 (39.9) 59 (47.2) 
46.2 (21.8) 50.1 (20.1) 0.11 
50.6 (17.7) 52.5 (19.1) 0.37 
236.9 (71.7) 237.4 (78.0) 0.95 
104.5 (44.2) 109.7 (40.1) 0.29 
733.9 (306.8) 813.9 (315.3) 0.03 
0.77 (0.42) 0.82 (0.42) 0.31 
53.2 (22.0) 57.9 (19.0) 0.05 
37.1 (7.7) 37.0 (9.0) 0.89 
54.0 (9.6) 52.7 (10.2) 0.24 
HAQ = Health Assessment Questionnaire; SF-36 = Medical Outcomes Study Short Form 36 
GAIT placebo responders had a shorter duration of OA symp- 
toms, lower WOMAC Function and lower HAQ Pain scores. 
Based on the variables in Table 1, we performed a logistic re- 
gression analysis to determine variables that were predictors of a 
higher placebo response rate. 
Table 2 
Variable Coefficient SE p-value 
Baseline WOMAC Function Score -0.00080 0.00038 0.036 
Duration of OA Symptoms (years) -0.0207 0.0129 0.11 
Baseline Acetaminophen Use 
(500mg tablets/day) -0.0885 0.0561 0.11 
These analyses demonstrated that higher WOMAC Function, 
longer duration of OA symptoms, and greater acetaminophen use 
are negatively associated with placebo response. 
Patients with more severe and longer duration of OA symptoms 
are less likely to be placebo responders. This may be an impor- 
tant consideration when planning OA clinical trials. 
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Hylan G-F 20 is a derivatized hyaluronan based viscosupplement 
for treating pain associated with osteoarthritis of the knee. Hylan 
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Abstract P165 - Fig. 1. Changes  in G' of hylan G-F 20 contrast groups as  function of incubation time at 37°C. 
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Abstract P165 - Fig. 2. Recovery of the contrast agents after mixing with hylan G-F 20 and incubation (CZE analysis). 
$86 Poster Presentat ions 
G-F 20 is also approved in the European Union and several other 
countries for treating osteoarthritis pain of the hip and is under 
an FDA approved investigational study for the hip as well. Be- 
cause injecting directly into the hip joint space is difficult, a con- 
trast agent is first injected to facilitate subsequent injection of the 
viscosupplement using fluoroscopic guidance. 
The purpose of this study was to determine the in vitro compat- 
ibility of hylan G-F 20 with commercially-available f uoroscopic 
contrast agents. Compatibility was defined as no change in rhe- 
ological properties, pH, appearance or chemical structure of the 
contrast agents and hylan G-F 20 mixtures when compared to a 
control (saline added to hylan G-F 20). 
Ionic dimer ioxaglate and non-ionic monomer iohexol represent 
the two classes of contrast agents used clinically and were cho- 
sen for investigation in this study. 
Methods: Ioxaglate or iohexol was aseptically mixed with hylan 
G-F 20 or saline at a 2:1 volume ratio. Following mixing, the sam- 
ples were stored at 37°C for 24, 48 and 72 hours and were eval- 
uated for the storage (G l) and loss modulii (G'), and viscosity. 
Contrast agent recovery, representing agent compatibility follow- 
ing mixing with hylan G-F 20, was analyzed by capillary zone 
electrophoresis (CZE). Each sample was tested in triplicate. 
Results: Dilution with either contrast agent did not adversely ef- 
fect hylan G-F 20 G' when compared to the saline control over 
3 days at 37°C (Fig. 1). Capillary zone electrophoresis analysis 
showed no change in elution time and good recovery (Fig. 2) of 
the contrast agents after mixing with hylan G-F 20 and incubation. 
Conclusions: We conclude that contrast agents used for hip in- 
jections are compatible with hylan G-F 20. We did not see any 
change in rheological properties, pH, and appearance of the con- 
trast agents and hylan G-F 20 mixtures when compared to a con- 
trol (saline added to hylan G-F 20). 
Additionally, we did not observe any significant change in contrast 
agent recovery or chemical interactions of contrast agents with 
hylan G-F 20. 
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Introduction: High tibial osteotomy (HTO) is recommended for 
people with moderate to severe medial knee OA (MKOA) to avoid 
or delay joint replacement. HTO is effective in restoring knee func- 
tion and reducing pain however many patients with good initial 
surgical outcomes continue developing pain and joint destruc- 
tion. The aim of this study was to investigate the effect of HTO 
on movement patterns in people with MKOA, focusing on charac- 
teristics affecting disease progression. 
Methods: Nine subjects with MKOA and genu varum were tested 
prior to (PRE) and at one (P1) and two (P2) years after HTO. Nine 
healthy controls with neutral alignment (NORM) were compared. 
Motion analysis was performed to assess kinematic and kinetic 
patterns during the stance phase of gait. Alignment and joint lax- 
ity were measured from radiographs. Quadriceps strength was 
assessed isometrically. Self-reported knee function and instability 
were analyzed. Independent -tests, paired t-tests and one-way 
ANOVA's for repeated measures were used to assess differences 
in groups and time frames. 
Results: After HTO the improved alignment, reduced laxity and 
reduced knee adduction angles and moments during walking re- 
mained unchanged after 2 years. Quadriceps strength was lower 
post-operatively and was lower than controls at 1 and 2 years 
(p=0.006). Knee flexion remained lower than controls (p= 0.049). 
Self-reported knee function improved but remained significantly 
lower than controls. Prior to surgery 6/9 subjects (67%) com- 
plained of knee instability and 5 reported improved stability af- 
ter 1 year. After 2 years, two subjects instability worsened and 
quadriceps weakness correlated with knee instability (r=0.576, 
p=0.056). 
Discussion: Improved alignment and laxity and reduced ad- 
duction angles and moments during walking persisted after two 
years. However, quadriceps strength and knee flexion during 
weight acceptance did not improve. Quadriceps weakness has 
been associated with reduced knee flexion during gait that could 
reduce shock absorption and hasten joint destruction. Quadri- 
ceps strength has also been associated with higher knee func- 
tion and may reduce the progression of MKOA. Yet rehabilitation 
to address quadriceps weakness following HTO is uncommon. 
Our work shows that people with MKOA complain of knee insta- 
bility that may be associated with high shear forces that are detri- 
mental to articular cartilage. Surgical realignment was successful 
at mitigating knee instability at one year but instability worsened 
thereafter. The correlation between quadriceps trength and knee 
instability suggests that despite realignment persistent weakness 
and instability could contribute to further joint degeneration. Re- 
habilitation, both non-operative and after HTO, should focus on 
quadriceps strength and improving joint stability to improve the 
long term function of people with MKOA. 
P167 
HIGH INTENSITY LASER THERAPY IN THE TREATMENT 
OF DEEP OSTEOCHONDRAL DEFETC. PILOT STUDY IN 
AN ANIMAL MODEL 
D Fortuna 1 , G Rossi 2, B Grigolo 3, R Buda 3, A Zati 3, TW 
Bilotta 3, S Giannini 3, P Mondardini 4, L Masotti 1 , A Crovace 5 
1EL.EN. Group, Scientific Committee, Calenzano, Florence, 
Italy; 2Veterinary Science Department, University of Camerino, 
Matelica, Italy; 3Laboratory of Immunology and Genetics, 
Rizzofi Orthopaedic Institute, Bologna, Italy; 41stituto Medicina 
Dello Sport, CONI, Bologna, Italy; 5Department of Emergency 
and Organ Transplantation, University of Bari, Valenzano, Bari, 
Italy 
Aim of the study: To investigate the effects of High Intensity 
Laser Therapy (HILT) as a new non- invasive method to stimu- 
late articular cartilage repair in vivo. 
Methods: Full thickness defects reaching the subchondral bone 
were created by mean of a surgical drill in the weight-bearing 
surface of the lateral femoral condyle of six sheeps. The wounds 
were then repaired using a new laser system (HILT): 3 out of the 
six sheeps received the laser treatment the other three were used 
as controls. 
Each treated subjetc received 15 treatments in 3 weeks of HILT 
laser system by EI.En. Group (Itlay). In our protocol we delivered 
19 kW/cm 2 of peak intensity and 2.5 J/cm 2 of fluence. 
To verify the efficacy of the treatment the cartilage tissues 
from the different animals were analysed at 21 (T1), 45 (T2) 
and 90 (T3) days by histological and immunohistological nal- 
yses. In particular the samples were stained with Safranin-O, 
Haematoxylin-Eosin, Alcian Pas and Herovici's stain. Mono and 
polyclonal antibodies specific to Vimentine, Ki67, ILGF-1, IL-lb, 
MMP-12 and collagen type I and II, were employed for immuno- 
histochemical evaluations. 
Results: The macroscopic observation of the defect areas 
showed a progressive growth of a new tissue from the edges to 
the central area of the lesions in the sheep treated with HILT. At 
T1 it was possible to evidentiate an increase in chondrocyte pro- 
liferation (high expression of ILGF 1 and Ki67) and a decrease 
of inflammatory factors (IL-1 b, MMP-1). On the contrary the con- 
trol group showed a severe tissue inflammation. At T/2 and T/3 
